Arterial Thrombosis - Pipeline Review, H2 2016

Arterial Thrombosis - Pipeline Review, H2 2016


  • Products Id :- GMDHC8444IDB
  • |
  • Pages: 61
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Arterial Thrombosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Arterial Thrombosis - Pipeline Review, H2 2016', provides an overview of the Arterial Thrombosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis

- The report reviews pipeline therapeutics for Arterial Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Arterial Thrombosis therapeutics and enlists all their major and minor projects

- The report assesses Arterial Thrombosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Arterial Thrombosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Arterial Thrombosis Overview 7

Therapeutics Development 8

Pipeline Products for Arterial Thrombosis - Overview 8

Pipeline Products for Arterial Thrombosis - Comparative Analysis 9

Arterial Thrombosis - Therapeutics under Development by Companies 10

Arterial Thrombosis - Therapeutics under Investigation by Universities/Institutes 11

Arterial Thrombosis - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Arterial Thrombosis - Products under Development by Companies 15

Arterial Thrombosis - Products under Investigation by Universities/Institutes 16

Arterial Thrombosis - Companies Involved in Therapeutics Development 17

Astellas Pharma Inc. 17

AstraZeneca Plc 18

Bayer AG 19

Bristol-Myers Squibb Company 20

Eisai Co., Ltd. 21

Johnson & Johnson 22

Sanofi 23

Thromboserin Ltd 24

TSRL, Inc. 25

Arterial Thrombosis - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

AS-1468240 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ASP-6537 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

BAY-1213790 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

BMS-593214 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

BMS-654457 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

C-3 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

E-5539 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ER-410660 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

FM-19 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

JNJ-375 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

PZ-128 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

SAR-216471 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

THL-001 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ticagrelor - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Arterial Thrombosis - Dormant Projects 57

Arterial Thrombosis - Product Development Milestones 58

Featured News & Press Releases 58

Nov 13, 2014: AstraZeneca announces initiation of development programme for BRILINTA reversal agent 58

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Figures

Number of Products under Development for Arterial Thrombosis, H2 2016 8

Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Top 10 Targets, H2 2016 27

Number of Products by Stage and Top 10 Targets, H2 2016 27

Number of Products by Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 31

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 33

Number of Products by Stage and Molecule Types, H2 2016 33

List of Tables

Number of Products under Development for Arterial Thrombosis, H2 2016 8

Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Arterial Thrombosis - Pipeline by Astellas Pharma Inc., H2 2016 17

Arterial Thrombosis - Pipeline by AstraZeneca Plc, H2 2016 18

Arterial Thrombosis - Pipeline by Bayer AG, H2 2016 19

Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 20

Arterial Thrombosis - Pipeline by Eisai Co., Ltd., H2 2016 21

Arterial Thrombosis - Pipeline by Johnson & Johnson, H2 2016 22

Arterial Thrombosis - Pipeline by Sanofi, H2 2016 23

Arterial Thrombosis - Pipeline by Thromboserin Ltd, H2 2016 24

Arterial Thrombosis - Pipeline by TSRL, Inc., H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 34

Arterial Thrombosis - Dormant Projects, H2 2016 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc.

AstraZeneca Plc

Bayer AG

Bristol-Myers Squibb Company

Eisai Co., Ltd.

Johnson & Johnson

Sanofi

Thromboserin Ltd

TSRL, Inc.

Arterial Thrombosis Therapeutic Products under Development, Key Players in Arterial Thrombosis Therapeutics, Arterial Thrombosis Pipeline Overview, Arterial Thrombosis Pipeline, Arterial Thrombosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 128960
Site License
USD 4000 INR 257920
Corporate User License
USD 6000 INR 386880

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com